Supplementary Figure 16 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

Multivariate Cox analysis of the change in fragment length score (FLS) from baseline to cycle 3 of pembrolizumab. Covariates in clude cohort, PD-L1 expression, and tumor mutation burden.